Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Non-Current Liabilities: 2013-2025

Historic Total Non-Current Liabilities for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $114.6 million.

  • Fortress Biotech's Total Non-Current Liabilities fell 16.99% to $114.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.6 million, marking a year-over-year decrease of 16.99%. This contributed to the annual value of $144.1 million for FY2024, which is 12.15% down from last year.
  • Per Fortress Biotech's latest filing, its Total Non-Current Liabilities stood at $114.6 million for Q3 2025, which was down 5.17% from $120.8 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Total Non-Current Liabilities peaked at $242.4 million during Q4 2022, and registered a low of $114.6 million during Q3 2025.
  • Over the past 3 years, Fortress Biotech's median Total Non-Current Liabilities value was $158.5 million (recorded in 2024), while the average stood at $159.1 million.
  • Per our database at Business Quant, Fortress Biotech's Total Non-Current Liabilities skyrocketed by 71.26% in 2021 and then slumped by 32.33% in 2023.
  • Fortress Biotech's Total Non-Current Liabilities (Quarterly) stood at $168.6 million in 2021, then surged by 43.80% to $242.4 million in 2022, then tumbled by 32.33% to $164.0 million in 2023, then declined by 12.15% to $144.1 million in 2024, then declined by 16.99% to $114.6 million in 2025.
  • Its Total Non-Current Liabilities was $114.6 million in Q3 2025, compared to $120.8 million in Q2 2025 and $143.9 million in Q1 2025.